Jasper Therapeutics (NASDAQ:JSPR) Earns Outperform Rating from Credit Suisse Group

Jasper Therapeutics (NASDAQ:JSPR – Get Rating)‘s stock had its “outperform” rating restated by Credit Suisse Group in a research note issued to investors on Thursday, Benzinga reports. They presently have a $4.00 price objective on the stock. Credit Suisse Group’s price objective would suggest a potential upside of 131.21% from the stock’s current price.

Other analysts also recently issued research reports about the company. Oppenheimer cut their price target on Jasper Therapeutics from $21.00 to $8.00 and set an “outperform” rating on the stock in a research note on Monday, November 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $6.00 target price on shares of Jasper Therapeutics in a report on Thursday. Finally, EF Hutton Acquisition Co. I restated a “buy” rating and set a $6.85 price objective on shares of Jasper Therapeutics in a research report on Thursday.

Jasper Therapeutics Trading Down 7.0 %

NASDAQ JSPR opened at $1.73 on Thursday. The stock has a 50-day moving average of $1.78 and a 200-day moving average of $1.23. The firm has a market cap of $65.71 million, a PE ratio of -1.68 and a beta of 2.01. Jasper Therapeutics has a 1-year low of $0.39 and a 1-year high of $4.62.

Insiders Place Their Bets

In other Jasper Therapeutics news, major shareholder Carlyle Group Inc. acquired 3,133,333 shares of the company’s stock in a transaction that occurred on Friday, January 27th. The stock was bought at an average price of $1.50 per share, with a total value of $4,699,999.50. Following the purchase, the insider now owns 8,761,891 shares in the company, valued at $13,142,836.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Jasper Therapeutics news, major shareholder Carlyle Group Inc. bought 3,133,333 shares of Jasper Therapeutics stock in a transaction on Friday, January 27th. The shares were bought at an average cost of $1.50 per share, for a total transaction of $4,699,999.50. Following the acquisition, the insider now directly owns 8,761,891 shares in the company, valued at $13,142,836.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Holding Ltd Roche sold 75,000 shares of the firm’s stock in a transaction on Wednesday, January 25th. The shares were sold at an average price of $1.89, for a total transaction of $141,750.00. Following the completion of the sale, the insider now owns 4,549,606 shares in the company, valued at $8,598,755.34. The disclosure for this sale can be found here. Insiders own 22.00% of the company’s stock.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its holdings in Jasper Therapeutics by 128.7% in the fourth quarter. Renaissance Technologies LLC now owns 65,400 shares of the company’s stock valued at $32,000 after acquiring an additional 36,800 shares in the last quarter. State Street Corp boosted its position in shares of Jasper Therapeutics by 51.2% during the 2nd quarter. State Street Corp now owns 32,884 shares of the company’s stock valued at $63,000 after purchasing an additional 11,132 shares in the last quarter. Forefront Analytics LLC boosted its position in shares of Jasper Therapeutics by 246.0% during the 3rd quarter. Forefront Analytics LLC now owns 119,800 shares of the company’s stock valued at $94,000 after purchasing an additional 85,175 shares in the last quarter. UBS Group AG lifted its stake in Jasper Therapeutics by 14.6% during the fourth quarter. UBS Group AG now owns 215,521 shares of the company’s stock valued at $103,000 after buying an additional 27,495 shares in the last quarter. Finally, Fernwood Investment Management LLC lifted its position in shares of Jasper Therapeutics by 53.1% in the fourth quarter. Fernwood Investment Management LLC now owns 454,706 shares of the company’s stock worth $220,000 after purchasing an additional 157,626 shares in the last quarter. 68.37% of the stock is currently owned by hedge funds and other institutional investors.

About Jasper Therapeutics

(Get Rating)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.